Paper
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Published Jun 1, 2019 · Deepak L. Bhatt, P. Steg, Michael Miller
Journal of the American College of Cardiology
Q1 SJR score
211
Citations
8
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
RCT
Large Human Trial
Highly CitedStudy Snapshot
Icosapent ethyl significantly reduces the burden of first, subsequent, and total ischemic events in statin-treated patients with elevated triglycerides and cardiovascular disease or diabetes.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease.
The REDUCE-IT trial showed that icosapent ethyl effectively reduced cardiovascular events and improved survival in patients with stable coronary artery disease.
2019·35citations·F. Picard et al.·Journal of the American College of Cardiology
Journal of the American College of Cardiology
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.
Alirocumab effectively reduces total nonfatal cardiovascular events and deaths in patients with acute coronary syndrome, providing a more comprehensive measure of its clinical efficacy.
2019·155citations·M. Szarek et al.·Journal of the American College of Cardiology
Journal of the American College of Cardiology
Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease
Lowering triglyceride levels and LDL-C levels both reduce the risk of coronary heart disease, but lowering triglyceride levels may be more effective for preventing cardiovascular events.
2019·484citations·B. Ference et al.·JAMA
JAMA
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Icosapent ethyl significantly reduces the risk of ischemic events in patients with elevated triglyceride levels, even in those receiving statin therapy.
2019·2097citations·Deepak L. Bhatt et al.·The New England Journal of Medicine
The New England Journal of Medicine
Citations
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial.
Icosapent ethyl reduces cardiovascular events in statin-treated patients with elevated triglycerides and high risk, regardless of baseline LDL-C levels.
2025·0citations·Rahul Aggarwal et al.·Journal of the American Heart Association
Journal of the American Heart Association
Long-term fasting induces a remodelling of fatty acid composition in erythrocyte membranes.
Long-term fasting triggers changes in fatty acid composition in erythrocyte membranes, leading to increased levels of omega-3 fatty acids and decreased levels of saturated and stearic acids.
2025·0citations·Katharina Gewecke et al.·European journal of clinical investigation
European journal of clinical investigation
Compare and Contrast of the Cellular Actions of Related Flavonoids, Apigenin and Chrysin
Apigenin and chrysin both have cholesterol-lowering properties, but apigenin has unique anti-oxidant and anti-inflammatory properties, potentially benefiting cardiovascular, renal, and cerebrovascular complications.
2024·0citations·Patrick Keefe et al.·Nutrients
Nutrients
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial.
CSL112 infusions significantly reduced the total burden of nonfatal ischemic events and cardiovascular death in high-risk patients after acute myocardial infarction compared to placebo.
2024·3citations·C. Gibson et al.·Journal of the American College of Cardiology
Journal of the American College of Cardiology
Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial.
Empagliflozin reduces hospitalizations and all-cause mortality by 24% compared to placebo in patients with T2DM and ASCVD, with sustained and consistent effects regardless of the reason for hospitalization.
2024·0citations·S. Inzucchi et al.·Diabetes research and clinical practice
Diabetes research and clinical practice
Pathophysiology and Clinical Management of Dyslipidemia in People Living with HIV: Sailing through Rough Seas
Dyslipidemia in people living with HIV is complex and influenced by various HAART agents, with statins being the cornerstone pharmacotherapy, but drug-drug interactions should be considered.
2024·4citations·Eleni Papantoniou et al.·Life
Life
Effect of statin add-on therapy on cardiovascular mortality
Statin add-on therapies, except icosapent ethyl, effectively reduce cardiovascular mortality, but only ezetimibe shows no significant difference in CV-related death rates.
2024·1citation·John R. Nelson et al.·Frontiers in Cardiovascular Medicine
Frontiers in Cardiovascular Medicine
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
Icosapent ethyl effectively reduces cardiovascular events across a range of Lp(a) levels, including those with clinically relevant elevations.
2024·5citations·M. Szarek et al.·Journal of the American College of Cardiology
Journal of the American College of Cardiology
Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial.
Icosapent ethyl (IPE) can modulate vascular regenerative cell content, suggesting a novel mechanism for its cardioprotective effects in the REDUCE-IT trial.
2024·0citations·E. Bakbak et al.·Med
Med